Search

Your search keyword '"Boers-Sonderen, Marye J."' showing total 338 results

Search Constraints

Start Over You searched for: Author "Boers-Sonderen, Marye J." Remove constraint Author: "Boers-Sonderen, Marye J."
338 results on '"Boers-Sonderen, Marye J."'

Search Results

1. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

2. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

3. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021

4. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

5. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III–IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy—What Can Be Learned From Progression?

6. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

7. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies

8. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma

9. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry

10. Adjuvant treatment with anti‐PD‐1 in acral melanoma: A nationwide study.

11. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors

12. Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry

13. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

14. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy

15. Baseline and on Treatment Biodistribution Variability of 18F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication

16. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

17. Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients

18. Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study

19. Long-Term Survival in Patients With Advanced Melanoma

20. Adjuvant treatment with anti-PD-1 in acral melanoma:A nationwide study

21. Long-Term Survival in Patients With Advanced Melanoma

22. Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients

23. BRAF/MEK inhibitor rechallenge in advanced melanoma patients

24. A prediction model for response to immune checkpoint inhibition in advanced melanoma

25. A prediction model for response to immune checkpoint inhibition in advanced melanoma

26. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?

27. BRAF/MEK inhibitor rechallenge in advanced melanoma patients

28. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021

29. Adjuvant dendritic cell therapy in stage IIIB/C melanoma:the MIND-DC randomized phase III trial

30. Improving survival in advanced melanoma patients:a trend analysis from 2013 to 2021

31. End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study

32. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients

33. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

35. Lower risk of severe checkpoint inhibitor toxicity in more advanced disease

36. A prediction model for response to immune checkpoint inhibition in advanced melanoma

37. BRAF/MEK inhibitor rechallenge in advanced melanoma patients

38. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III–IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy—What Can Be Learned From Progression?

39. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands

40. BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma

41. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

43. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases

45. A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

46. Supplementary Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry

47. Adjuvant treatment of in‐transit melanoma: Narrowing the knowledge gap left by clinical trials

48. Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma

49. A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

50. ASO Visual Abstract:Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Catalog

Books, media, physical & digital resources